Advancing a class on top of statins
World Class Leadership

Medical and Scientific Advisory Board

Dyslipidemia
John Kastelein
John Kastelein

MD, PhD, FESC

Dr. Kastelein is a Medical Advisory Board member for Gemphire. Dr. Kastelein is Professor of Medicine, Chairman of the Department of Vascular Medicine, and Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. In 2014, he was the Robert Levy Memorial Lecturer at American Heart Association Scientific Sessions. Dr. Kastelein has published over 740 research papers and he was one of the 3000 Highly Cited Researchers in 2014.

Evan Stein
Evan A. Stein

MD, PhD, FRCPC, FCAP

Dr. Stein is a Medical Advisory Board member for Gemphire. Dr. Stein is the director of the Cholesterol Treatment Center, and Director of the Metabolic and Atherosclerosis Research Center in Cincinnati. He is also the Voluntary Professor at the Pathology and Laboratory Medicine at the University of Cincinnati Medical Center. Dr. Stein is the Managing Partner of EVLIN Consultants. He founded PPD Global Central Labs in 1988, and he was an executive officer of Medpace Reference Laboratories.

Robert Hegele
Robert Hegele

MD, FRCPC, FACP, FAHA, FCAHS

Dr. Hegele is a Medical Advisory Board member for Gemphire. Dr. Hegele is a distinguished professor and research scientist of Robarts Research Institute and director of the Blackburn Cardiovascular Genetics Lab and London Regional Genomics Centre. He has over 600 publications and he was awarded for The Journal of Lipid Research Lectureship Award, 2012 Kern Lipid Conference.

Dirk Blom
Dirk Blom

PhD

Dr. Blom is a Medical Advisory Board member for Gemphire. Dr. Blom is the head of the Division of Lipidology at the University of Cape Town, head of the Lipid Clinic at Groote Schuur Hospital, and the member of executive committee of the Lipid and Atherosclerosis Society of Southern Africa. Dr. Blom is a member of South African Medical Association and South African Heart Association.

Harold Bays
Harold Bays

MD, FTOS, FACC, FACE, FNLA

Dr. Bays is a Medical and Scientific Advisory Board member for Gemphire. He has served as an Investigator in over 400 Phase I - IV clinical trials for treatments for high cholesterol and other dyslipidemias, obesity, diabetes mellitus, hypertension, osteoporosis, and other metabolic and hormonal disorders. Dr. Bays has served as Medical Director of L-MARC Research Center since 1989, and has served as President of L-MARC Research Center since its independent incorporation in 1998.

NASH
Rohit Loomba
Rohit Loomba

MD, MHSc

Dr. Loomba is a Medical and Scientific Advisory Board member for Gemphire. He is an expert in the clinical management of chronic liver diseases and holds a joint appointment in the Division of Gastroenterology in the Department of Medicine and the Division of Epidemiology in the Department of Family and Preventive Medicine, University of California at San Diego School of Medicine. Dr. Loomba’s research focuses on all aspects of nonalcoholic fatty liver disease including aging, epidemiology, genetic and environmental predisposition, natural history, and treatment of nonalcoholic steatohepatitis (NASH).

Mechanism
Kevin Jon Williams
Kevin Jon Williams

M.D.

Dr. Williams is a Medical and Scientific Advisory Board member for Gemphire. An avid researcher with many published works to his credit, Dr. Williams has performed groundbreaking studies in the areas of lipoproteins, atherosclerosis, and more recently, type 2 diabetes. Examples include the ‘Response-to-Retention’ hypothesis of early atherogenesis, identification of sulfatase-2 as an inhibitor of atherogenic remnant lipoprotein removal by the liver in type 2 diabetes, and discovery of the NSAPP oxide transport chain, which is a key regulator of balanced insulin signaling. Dr. Williams serves on the editorial board of Arteriosclerosis, Thrombosis and Vascular Biology (an American Heart Association journal) and Rambam (Maimonides) Medical Journal.